Market Overview:
The global influenza medications market size is expected to reach USD 1,386.21 million by 2032, exhibiting the CAGR of 4.3% during the forecast period.
Market Introduction
Influenza, commonly referred to as flu, is a viral infection that affects the throat, nose, and lungs. The symptoms of flu usually come on suddenly and take the form of cough, sore throat, fever, runny nose, headaches, and fatigue. Flu typically causes mild illness, but negligence can lead to severe illness or even death. The symptoms of influenza can be managed by taking ample rest and consuming plenty of fluids. But in case of a more severe infection, healthcare professionals may prescribe an antiviral medicine for treating the flu. These medications can take the form of oseltamivir, baloxavir, and zanamivir. Baloxavir and oseltamivir are intended for oral consumption, whereas zanamivir is inhaled using a device similar to an asthma inhaler.
Download Free Sample PDF Copy of the Report:
Industry Participants
The market for influenza medications is fragmented. The major industry participants are competing on numerous factors to gain a larger share of the industry. Some of the top players operating in the market are:
- AbbVie (US)
- AstraZeneca (UK)
- Bayer AG (Germany)
- Bharat Biotech (India)
- BioCryst Pharmaceuticals (US)
- Daiichi Sankyo (Japan)
- Mylan (US)
- Novartis AG (Switzerland)
- Roche Diagnostics (Switzerland)
- Sanofi SA (France)
- Seqirus (Australia)
Segmental Analysis
- The influenza medications market segmentation is primarily based on influenza type, treatment, distribution channel, and region.
- By influenza type insights, the influenza A segment accounted for the largest market share owing to the rising number of cases of this influenza type.
- By treatment insights, the oseltamivir segment held the maximum revenue share due to its widespread adoption as a prescribed drug.
Influenza Medications Market, Influenza Type Outlook (Revenue – USD Million, 2019-2032)
- Influenza A
- Influenza B
Influenza Medications Market, Treatment Outlook (Revenue – USD Million, 2019-2032)
- Baloxavir Marboxil
- Oseltamivir Phosphate
- Others
Influenza Medications Market, Distribution Channel Outlook (Revenue – USD Million, 2019-2032)
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Recent Developments in the Influenza Vaccine Industry:
- September 2023 – Moderna:
Moderna announced that its new flu vaccine, mRNA-1010, successfully met its primary endpoint in a Phase 3 trial. The vaccine demonstrated improved immunogenicity across various age groups, particularly in older populations, marking a significant advancement in flu vaccine development. This success reinforces Moderna’s position as a leader in mRNA vaccine technology, further supporting its potential for enhancing seasonal influenza prevention. - September 2022 – Pfizer:
Pfizer successfully completed recruitment for its Phase 3 clinical trial to evaluate the safety, efficacy, and tolerability of its quadrivalent modified influenza vaccine. This vaccine aims to offer broader protection against multiple strains of influenza, and the trial is a pivotal step in its regulatory approval and commercialization.
The proliferation of seasonal flu, greater prevalence of contagious respiratory illness, and increasing patient population who are at higher risk of developing flu-related complications, are key factors driving the market growth. Growing number of government initiatives like vaccination programs for controlling the spread of influenza and awareness regarding the importance of early diagnosis and treatment of influenza, are further anticipated to propel market growth.